Back to Blog

Dekel Gelbman, CEO of FDNA, on "Next-Generation Phenotyping"

Simon Smith

For the inaugural episode of our Artificial Intelligence in Drug Discovery podcast, I spoke with Dekel Gelbman, CEO of FDNA. FDNA enables precision medicine by using artificial intelligence for next-generation phenotyping. Their technology links genetic traits with phenotypic characteristics such as facial structure.

Listen now to learn what inspired the technology, the problems it solves, how it can help in the drug discovery process, and where FDNA plans to take it:

Topics: Artificial Intelligence in Drug Discovery

Written by
Simon Smith

Never Miss a Blog Post!